Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityOther Accumulated ExpensesPayablesReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Marker Therapeutics (MRKR) Non-Current Assets (2018 - 2023)

Marker Therapeutics (MRKR) has disclosed Non-Current Assets for 6 consecutive years, with $17.0 million as the latest value for Q1 2023.

  • Quarterly Non-Current Assets fell 28.87% to $17.0 million in Q1 2023 from the year-ago period, while the trailing twelve-month figure was $17.0 million through Mar 2023, down 28.87% year-over-year, with the annual reading at $17.8 million for FY2022, 19.64% down from the prior year.
  • Non-Current Assets for Q1 2023 was $17.0 million at Marker Therapeutics, down from $17.8 million in the prior quarter.
  • The five-year high for Non-Current Assets was $23.9 million in Q1 2022, with the low at $872702.0 in Q4 2019.
  • Average Non-Current Assets over 5 years is $14.3 million, with a median of $18.2 million recorded in 2020.
  • The sharpest move saw Non-Current Assets soared 2329.69% in 2020, then fell 28.87% in 2023.
  • Over 5 years, Non-Current Assets stood at $872702.0 in 2019, then skyrocketed by 2329.69% to $21.2 million in 2020, then increased by 4.48% to $22.2 million in 2021, then fell by 19.64% to $17.8 million in 2022, then decreased by 4.35% to $17.0 million in 2023.
  • According to Business Quant data, Non-Current Assets over the past three periods came in at $17.0 million, $17.8 million, and $18.7 million for Q1 2023, Q4 2022, and Q3 2022 respectively.